Journals / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 1

Mortality in heart failure patients

Pages
63–68
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with HF and reduced ejection fraction have higher mortality rates, most commonly due to cardiovascular causes, compared with patients HF and preserved ejection fraction.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Heart failure (HF) is a clinical syndrome, which is becoming a major public health problem in recent decades, due to its increasing prevalence, especially in the developed countries, mostly due to prolonged lifespan of the general population as well as the increased of HF patients.
📊
Key Findings & Data:The HF treatment, particularly, new pharmacological and non-pharmacological agents, has markedly improved clinical outcomes of patients with HF including increased life expectancy and improved quality of life.
💡
Conclusion & Impact:Patients with HF and reduced ejection fraction have higher mortality rates, most commonly due to cardiovascular causes, compared with patients HF and preserved ejection fraction.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Heart failure (HF) is a clinical syndrome, which is becoming a major public health problem in recent decades, due to its increasing prevalence, especially in the developed countries, mostly due to prolonged lifespan of the general population as well as the increased of HF patients. The HF treatment, particularly, new pharmacological and non-pharmacological agents, has markedly improved clinical outcomes of patients with HF including increased life expectancy and improved quality of life. However, despite the facts that mortality in HF patients has decreased, it still remains unacceptably high. This review of summarizes the evidence to date about the mortality of HF patients. Despite the impressive achievements in the pharmacological and non-pharmacological treatment of HF patients which has undeniably improved the survival of these patients, the mortality still remains high particularly among elderly, male and African-American patients. Patients with HF and reduced ejection fraction have higher mortality rates, most commonly due to cardiovascular causes, compared with patients HF and preserved ejection fraction.

🔖

Cite This Article

BYTYÇİ, I., BAJRAKTARI, G. (2015). Mortality in heart failure patients. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 1, 63–68. https://ajindex.com/articles/365895

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Roger VL. Epidemiology of heart failure. Circ Res 2013
  2. [CrossRef] Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011
  3. [CrossRef] Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007
  4. [CrossRef] Loh JC, Creaser J, Rourke DA, Livingston N, Harrison TK, Vandenbogaart E, et al. Temporal trends in treatment and out- comes for advanced heart failure with reduced ejection fraction from 1993-2010: findings from a university referral center. Circ Heart Fail 2013
  5. [CrossRef] Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease etiology and risk factors to heart failure with preserved or reduced ejection fraction. Circulation 2009
  6. [CrossRef] Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005
  7. [CrossRef] Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011
  8. [CrossRef] Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, et al. Hospitalizations after heart failure diagnosis a com- munity perspective. J Am Coll Cardiol 2009
  9. [CrossRef] Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost- effectiveness of heart failure therapies. Nat Rev Cardiol 2013
  10. [CrossRef] Friedrich EB, Böhm M. Management of end-stage heart failure. Heart 2007
  11. [CrossRef] Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002
  12. [CrossRef] Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001
  13. [CrossRef] Gomez-Soto FM, Andrey JL, Garcia-Egido AA, Escobar MA, Romero SP, Garcia-Arjona R, et al. Incidence and mortality of heart failure: a community-based study. Int J Cardiol 2011
  14. [CrossRef] Mehta PA, Dubrey SW, McIntyre HF, Walker DM, Hardman SM, Sutton GC, et al. Improving survival in the 6 months after diagnosis of heart failure in the past decade: population-based data from the UK. Heart 2009
  15. [CrossRef] Laribi S, Aouba A, Nikolaou M, Lassus J, Cohen-Solal A, Plaisance P, et al. Trends in death attributed to heart failure over the past two decades in Europe. Eur J